missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Human ErbB3/Her3 Antibody, R&D Systems™

Mouse Monoclonal Antibody
Brand: R&D Systems MAB348-100
This item is not returnable.
View return policy
Description
ErbB3/Her3 Monoclonal specifically detects ErbB3/Her3 in Human samples. It is validated for Western Blot, Immunohistochemistry.
Specifications
| ErbB3/Her3 | |
| Monoclonal | |
| Unconjugated | |
| Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative | |
| c-erbB3, EC 2.7.10, EC 2.7.10.1, ErbB-3, erbB3-S, HER3, HER3c-erbB-3, LCCS2, lethal congenital contracture syndrome 2, MDA-BF-1, MGC88033, p180-ErbB3, p45-sErbB3, p85-sErbB3, Proto-oncogene-like protein c-ErbB-3, receptor tyrosine-protein kinase erbB-3, Tyrosine kinase-type cell surface receptor HER3, v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) | |
| Mouse | |
| Protein A or G purified from ascites | |
| RUO | |
| 2065 | |
| Reconstitute at 0.5 mg/mL in sterile PBS. | |
| Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. | |
| IgG1 |
| Western Blot, Immunohistochemistry | |
| 66219 | |
| Western Blot 1 ug/mL, Immunohistochemistry 8-25 ug/mL | |
| P21860 | |
| ERBB3 | |
| Mouse myeloma cell line NS0-derived recombinant human ErbB3 Ser20-Thr643 Accession # P21860 | |
| 100 μg | |
| Primary | |
| Detects human ErbB3 in direct ELISAs and Western blots. In direct ELISAs and Western blots, this antibody shows no cross-reactivity with recombinant human (rh) EGF R, rhErbB4, or rhErbB2. | |
| Human | |
| Ascites |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction